Is there a role for Bcl-2 directed treatment for patients with translocation 11;14?

FAQ Library published on October 11, 2017
Download Transcript Download Audio
Sagar Lonial, MD, FACP
Chair and Professor
Department of Hematology and Medical Oncology
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Welcome to Managing Myeloma. I am Dr. Sagar Lonial. I am frequently asked, “Is there a role for Bcl-2 directed treatment for patients with translocation 11;14?” I think that this is really an important and exciting question. For years we have been talking about using biomarker-directed therapy in all of cancer, and in myeloma, we do not really have biomarker-directed therapy. What we know about the Bcl-2 inhibitor venetoclax* is that it does seem to have preferential activity in the context of patients with the 11;14 translocation. There is a lot of really good biology to evaluate this and try and understand why this is. If one looks at a single-agent response rate of venetoclax in relapsed/refractory myeloma for 11;14 translocated patients, the overall response rate is about 40%. If you add dexamethasone to that (venetoclax-dexamethasone for 11;14 translocated myeloma), the response rate jumps to 60%.

We at Emory have a system where we do BH3 profiling and can identify whether that response rate can even be higher based on sensitivity to venetoclax in vitro using assays. With that approach, we have been able to significantly and effectively predict almost all of our patients responding versus not responding to a Bcl-2 directed therapy like venetoclax. I think clearly there is a role for 11;14 directed therapy with Bcl-2 inhibition; the question is, can we expand it even beyond that? There is very exciting data coming from Philippe Moreau and another collaborative group evaluating venetoclax in combination with bortezomib and dexamethasone, suggesting that even in non-11;14 patients, you may be able to overcome bortezomib resistance by adding in venetoclax in a small subset of patients. I think there is more to the story here to come. The use of bortezomib and venetoclax is clearly very active. Venetoclax-dexamethasone in 11;14 positive patients does represent a biomarker-driven therapy and one that I think we are all very excited about. Thank you for viewing this activity.

*Venetoclax has not been approved by the FDA for the treatment of multiple myeloma at any stage of the disease

Last modified: October 10, 2017
Related Items by Author
Are there certain agents which can be selected for treatment which may lessen immunosuppression?
Sagar Lonial, MD, FACP
FAQ Library published on May 20, 2020
Will clinical trials continue to enroll during this time?
Sagar Lonial, MD, FACP
FAQ Library published on May 20, 2020
What education or instruction are you providing to your patients with myeloma who are already immunocompromised?
Sagar Lonial, MD, FACP
FAQ Library published on May 20, 2020
How are you managing care delivery during the COVID-19 pandemic?
Sagar Lonial, MD, FACP
FAQ Library published on May 20, 2020
Practice-changing trials to watch for in 2018
Sagar Lonial, MD, FACP
FAQ Library published on January 24, 2018
A key educational message from ASH 2017
Sagar Lonial, MD, FACP
FAQ Library published on January 12, 2018
How will the new IMWG definition of active multiple myeloma impact clinical practice?
Sagar Lonial, MD, FACP
FAQ Library published on August 18, 2016
How do we determine which patients will benefit the most from treatment with daratumumab and elotuzumab?
Sagar Lonial, MD, FACP
FAQ Library published on July 18, 2016
What is the role of SPEP, UPEP and immunofixation in managing multiple myeloma patients?
Sagar Lonial, MD, FACP
FAQ Library published on July 6, 2016
Is BD or KD a standard of care in relapsed/refractory multiple myeloma?
Sagar Lonial, MD, FACP
FAQ Library published on June 15, 2016